Jommi, C., & Cavazza, M. (2019). Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals. Global and Regional Health Technology Assessment, 6(1). https://doi.org/10.33393/grhta.2019.460